Source comparison
Best Thymosin Alpha-1 Dosage for Hepatitis 2026: Protocol Comparison
PHRI-HBV (Combination) 1.6mg SC twice weekly + entecavir 48 weeks HBeAg seroconversion at week 72 32.1% vs 18.7% monotherapy Injection site erythema (12%), transient fever (8%) Gold standard for treatment-naïve chronic HBV. Seroconversion benefit justifies ext
This comparison does not assign a generated winner or score.
- PHRI-HBV (Combination)
- 1.6mg SC twice weekly + entecavir
- 48 weeks
- HBeAg seroconversion at week 72
- 32.1% vs 18.7% monotherapy
- Injection site erythema (12%), transient fever (8%)
- Gold standard for treatment-naïve chronic HBV. Seroconversion benefit justifies extended protocol
- Italian Multicentre HBV
- 3.2mg SC twice weekly
- 24 weeks
- ALT normalisation + HBV DNA suppression
- Not measured (focused on biochemical response)
- Injection site reactions (18%), headache (14%)
- Higher dose produced no additional ALT benefit vs 1.6mg. Discontinued due to cost-benefit analysis
- HCV Salvage (Genotype 1b)
- 1.6mg SC twice weekly + PEG-IFN + RBV
- SVR at week 24 post-treatment
- N/A (HCV protocol)
- Consistent with interferon-based therapy. No additive toxicity
- Relevant only for DAA-ineligible patients in 2026. Historical importance for HCV resistance contexts
- Korean Long-Duration HBV
- 1.6mg SC twice weekly
- 52 weeks
- Durable HBeAg loss at 1-year follow-up
- 41.2% sustained loss vs 28.9% at 24 weeks
- Similar to 24-week protocols. No cumulative toxicity signal
- Extended duration doubles durable response in high-baseline-viral-load populations (>10^7 IU/mL)
- The twice-weekly 1.6mg regimen for 24–48 weeks represents the intersection of efficacy, tolerability, and practical adherence. Escalating to 3.2mg produced marginal biochemical improvements but failed to shift hard endpoints like seroconversion or sustained viral suppression. The immune system's response ceiling is reached at lower doses when protocol duration is adequate.